Proteomic profiling for detection of early-stage heart failure in the community

27 August 2021 (00:00 - 00:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Assistant Professor Nicholas Cauwenberghs

University of Leuven, Leuven (Belgium)

46 More presentations in this session

Presentation thumbnail

Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes

Doctor A. Sharma (Montreal, CA)

Abstract Slides

Presentation thumbnail

SGLT-2 inhibitors in patients with and without a history of heart failure: a meta-analysis

Doctor V. Razuk (New York City, US)

Abstract Slides

Presentation thumbnail

Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis

Doctor G. Steiner-Gager (Vienna, AT)

Abstract Slides

Presentation thumbnail

Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin

Doctor J. Kolwelter (Erlangen, DE)

Abstract Slides

Presentation thumbnail

Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial

Doctor M. Senni (Bergamo, IT)

Abstract Slides

Access the full session

Session thumbnail

Congress committee e-posters choice in heart failure

The Event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

You may be interested in

Congress Session

From genetic signatures to clinical implications

Congress Presentation

A proteo-genomic discovery approach to identify markers of early heart failure

Congress Presentation

CA125 assessment using ABEI-based assay in heart failure: implications for disease severity and cardiac biomarkers

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources